Adults 40 to 65, any sex, with Physical Activity or Life Style. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Difference in Percentage of Time Spent Per Physical Activity Level Per Week of Time, Between the Three Different Groups Measured by Activity Monitor Actigraph (GT3X)Primary· Baseline ,6 months.
Each individual will wear an activity monitor for 7 days. This will be done at baseline and after 6 months. The difference in the time of physical activity level was measured in minutes of activity during a week and then divided into percentages of sedentary time, light physical activity time and moderate to vigourous physical activity time, measured by activity monitor Actigraph (GT3X). In the analysis
Baseline:Percent of time in sedentary time
Group
Value
95% CI
PAP Only
66.2
± 6.7
Mindfulness Only
65.5
± 9.2
Combination of the Two Groups
66.7
± 8.8
Baseline:Percent of time in LIPA
Group
Value
95% CI
PAP Only
30.9
± 6.2
Mindfulness Only
31.7
± 8.2
Combination of the Two Groups
30.3
± 8.0
Baseline:Percent of time in MVPA
Group
Value
95% CI
PAP Only
2.6
± 0.18
Mindfulness Only
2.3
± 0.02
Combination of the Two Groups
2.4
± 0.02
6 months:Percent of time in sedentary time
Group
Value
95% CI
PAP Only
65.0
± 6.8
Mindfulness Only
65.9
± 9.4
Combination of the Two Groups
64.0
± 9.1
6 months Percent of LIPA
Group
Value
95% CI
PAP Only
32.0
± 5.8
Mindfulness Only
31.6
± 9.0
Combination of the Two Groups
32.8
± 8.9
6 months: Percent of MVPA
Group
Value
95% CI
PAP Only
2.6
± 0.02
Mindfulness Only
1.9
± 0.02
Combination of the Two Groups
2.7
± 0.02
Difference Between the Three Groups in Revised Assessment of Their Self-rated HealthSecondary· base-line ,3 months, 6 months
assessment based on terms of perceived health with five alternative answers, a higher score incdicates a better outcome
1. very poor
2. poor
3. fair
4. good
5. very good
Baseline
Group
Value
95% CI
PAP Only
3
1 – 4
Mindfulness Only
3
2 – 5
Combination of the Two Groups
3
2 – 5
3 months
Group
Value
95% CI
PAP Only
3
1 – 4
Mindfulness Only
3
2 – 5
Combination of the Two Groups
4
2 – 5
6 months
Group
Value
95% CI
PAP Only
4
1 – 4
Mindfulness Only
4
2 – 5
Combination of the Two Groups
4
2 – 5
Difference Between Groups in the Amount of Self-perceived Sleep ProblemsSecondary· Baseline, 3 months, 6 months
Insomnia Severity Index(ISI); is a self-report questionnaire measuring insomnia symptoms to evaluate the degree of insomnia. The scale consists of seven questions that evaluate Sleep mode, sleep during the night, waking up early, the feeling of being rested, how sleeping problems affect daily life, and how sleep patterns concern the individual. The higher the score, the better the outcome. Minimun score = 0, Maximum score = 28
Insomnia Severity Index baseline
Group
Value
95% CI
PAP Only
8
0 – 24
Mindfulness Only
11
0 – 27
Combination of the Two Groups
10
0 – 21
Insomnia Severity Index 3 months
Group
Value
95% CI
PAP Only
7
0 – 20
Mindfulness Only
11
0 – 27
Combination of the Two Groups
9
0 – 27
Insomnia Severity Index 6 months
Group
Value
95% CI
PAP Only
6
0 – 18
Mindfulness Only
13
0 – 25
Combination of the Two Groups
9
0 – 18
Sponsor's own description
In a pilot study, 90 physically inactive patients will be opportunistically and consecutively recruited and randomized to three intervention groups: mindfulness training, Physical Activity on Prescription (PAP) or only PAP. Follow-up will be done at baseline, three and six months with questionnaires, accelerometers and analysis of traditional risk factors to evaluate whether mindfulness may increase physical activity and decrease physical inactivity.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06003712 — Exploring the Effect of Mindfulness on Quality of Life (QoL) in Spinal Cord Injury (SCI)
· NA
· not yet recruiting
NCT07210567 — Mindfulness-based Ecological Momentary Intervention for Smoking Cessation Among Cancer Survivors
· NA
· recruiting
NCT07335159 — Does Patient Testimonial Improve the Pain Relief Derived From a Brief Intervention
· NA
· recruiting
NCT07216417 — TeleYoga for Chronic Low Back Pain: A Quantitative and Qualitative Study
· NA
· active not recruiting
NCT07346339 — Sensory Mindfulness for NICU Mothers: Effects on Breast Milk, Well-Being, and Stress
· NA
· completed
Other recruiting trials for Physical Activity
Currently open trials in the same condition.
NCT07466797 — The eHealth Integrated Maternal Physical Activity Programme in Prenatal Care Trial (E-IMPACT)
· NA
· recruiting
NCT07466914 — Constipation in Children With Cerebral Palsy
· active not recruiting
NCT07290309 — Survivors Uniting for Remote Guided Exercise
· NA
· recruiting
NCT07415460 — Evaluating the Impact of SKY Breath Meditation on Stress, Well-being, and Connection in College Students
· NA
· recruiting
NCT07585409 — Physical Activity in Persons With Parkinson's Disease
· recruiting
Other Region Skane trials
Trials by the same sponsor.
NCT07511673 — The Study is a Randomised Clinical Trial (RCT) to Test if Preoperative Dental Screening is Superior to no Preoperative D
· NA
· not yet recruiting
NCT07169747 — Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young
· Phase 2
· recruiting
NCT07494669 — Proteomics and Physiological Parameters Predicting Complications After Colorectal Cancer Surgery
· not yet recruiting
NCT07462351 — System-integrated Point-of-Care Ultrasound in Breast Cancer Screening
· NA
· recruiting
NCT06975696 — Fusion Imaging in Endovascular Thrombectomy for Acute Ischemic Stroke
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Region Skane
Last refreshed: 16 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02869854.